Search clinical trials for: Sm-p80 GLA-SE

Total 49 results

National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

Schistosomiasis

United States
International Vaccine Institute

Recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar

Schistosomiasis

Burkina Faso, Madagascar
Leiden University Medical Center
MRC/UVRI and LSHTM Uganda Research Unit; Texas Tech University Health Sciences...

Not yet recruiting

Sm-p80 Schistosomiasis Challenge Study

Schistosomiasis | Schistosoma Mansoni
IDRI
Bill and Melinda Gates Foundation

Completed

Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers

Visceral Leishmaniasis

United States
IDRI
Rockefeller University

Completed

The Effects of GLA (5 mcg) on Human Volunteers

Healthy Volunteers

United States
National Institute of Allergy and Infectious Diseases...

Completed

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

Leishmaniasis

United States
U.S. Army Medical Research and Development Command
United States Agency for International Development (USAID); IDRI

Completed

Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults

Malaria

United States
The Immunobiological Technology Institute (Bio-Manguinhos)...
Oswaldo Cruz Institute

Not yet recruiting

Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients

Leprosy

Brazil
Access to Advanced Health Institute (AAHI)
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

Pulmonary TB

United States
Quratis Inc.

Unknown

Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent

Tuberculosis

Korea, Republic of
Quratis Inc.
IDRI

Unknown

Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers

Tuberculosis

Korea, Republic of
IDRI
American Leprosy Missions

Completed

Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Leprosy

United States
Immune Design

Completed

A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

Merkel Cell Carcinoma

United States
IDRI
South African Tuberculosis Vaccine Initiative; Aeras

Completed

Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers

Pulmonary Tuberculosis

South Africa
Rockefeller University
Immune Design; IDRI Corporation

Completed

The Effects of GLA on Human Volunteers

Healthy Volunteers

United States
IDRI
Aeras; Paul G. Allen Family Foundation

Completed

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Pulmonary Tuberculosis

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

Tuberculosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States
Oswaldo Cruz Foundation

Recruiting

Anti-Schistosomiasis Sm14-vaccine in Senegal

Vaccination; Infection | Schistosomiasis Mansoni | Schistosomiasis Haematobium

Senegal
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants (HVTN 135)

HIV Infections

South Africa
Mayo Clinic
National Cancer Institute (NCI)

Completed

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma

United States
IDRI

Completed

Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers

Leishmaniasis

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

HIV Infections

United States
Oswaldo Cruz Foundation
IDRI; Biomedical Research Center EPLS; Orygen Biotecnologia SA

Completed

Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

Schistosomiasis

Senegal
Oswaldo Cruz Foundation
IDRI; Biomedical Research Center EPLS; Orygen Biotecnologia SA

Completed

Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions

Schistosomiasis

Senegal
IDRI
Wellcome Trust; South African Tuberculosis Vaccine Initiative

Completed

Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion

Pulmonary Tuberculosis

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

HIV Infections

United States
University Hospital Tuebingen
University of Copenhagen; Institut de Recherche pour le Developpement; Université... and other collaborators

Completed

Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted (PAMVAC)

Malaria, Antepartum

Benin
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

Schistosomiasis

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

Tuberculosis, Pulmonary
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaborators

Active, not recruiting

Evaluating the Safety and Immunogenicity of HIV-1 Vaccines Based on Chimpanzee Serotypes of Ad Expressing Clade C gp140 and a CH505TF gp120 Protein Boost in Healthy, HIV- Uninfected Adult Participants (HVTN139)

HIV Infections

South Africa
Gustave Roussy, Cancer Campus, Grand Paris

Withdrawn

Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy (ISILI)

Colorectal Cancer Metastatic

France
Institut National de la Santé Et de la Recherche...
EVI Industries, Inc.; Recherche Clinique Paris Descartes Necker Cochin Sainte... and other collaborators

Completed

Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults (PRIMALVAC)

Malaria

Burkina Faso, France
Medicago
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Completed

Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
Immune Design
Merck Sharp & Dohme LLC

Terminated

Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)

Follicular Low Grade Non-Hodgkin's Lymphoma
National Institute of Allergy and Infectious Diseases...

Completed

A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults

Schistosomiasis

Brazil
Institut National de la Santé Et de la Recherche...
EVI Industries, Inc.; BPRC; Recherche Clinique Paris Descartes Necker Cochin... and other collaborators

Completed

Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults (AMA1-DiCo)

Malaria, Falciparum

Burkina Faso, France
Worcester HIV Vaccine
Brigham and Women's Hospital; Access to Advanced Health Institute (AAHI)

Completed

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

HIV Infections

United States
Mapi Pharma Ltd.

Active, not recruiting

Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS

Multiple Sclerosis

Israel
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

HIV Infections

United States
Institut Bergonié
Merck Sharp & Dohme LLC; Ministry of Health, France; Immune Design

Active, not recruiting

Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)

Sarcoma

France
Seagen Inc.

Active, not recruiting

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02)

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Korea, Republic of, United Kingdom, Taiwan, Canada, Australia
Universität Münster

Recruiting

Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis (CLAProMS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Hospital do Rim e Hipertensão

Not yet recruiting

Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

CMV Infection
Anu Sharma

Terminated

Propranolol in Treating Hypoglycemia Unawareness

Type 1 Diabetes Mellitus

United States
Jonsson Comprehensive Cancer Center
Arcus Biosciences, Inc.

Suspended

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Borderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Suspended

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Breast Carcinoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Breast Cancer AJCC v6 and v7 | Breast Adenocarcinoma and other conditions

United States
Children's Oncology Group

Recruiting

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia

United States, Australia, Canada

Search clinical trials for: Sm-p80 GLA-SE

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations